<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recommendations for treatment with specific antidementia drugs in Denmark are given on the basis of recent evidence </plain></SENT>
<SENT sid="1" pm="."><plain>Such evidence supports treatment of mild to moderate <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> (AD) with <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitors</z:chebi> (AchEI), and moderate to severe AD with memantine </plain></SENT>
<SENT sid="2" pm="."><plain>Combination therapy with these drugs can be considered in moderate AD </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000726'>Dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> with <z:hpo ids='HP_0000726'>dementia</z:hpo> should be treated with rivastigmine </plain></SENT>
<SENT sid="4" pm="."><plain>There is not sufficient evidence to recommend treatment with AchEI or memantine in pure vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> or <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> </plain></SENT>
</text></document>